Literature DB >> 9003938

An economic approach to clinical trial design and research priority-setting.

K Claxton1, J Posnett.   

Abstract

Whilst significant advances have been made in persuading clinical researchers of the value of conducting economic evaluation alongside clinical trials, a number of problems remain. The most fundamental is the fact that economic principles are almost entirely ignored in the traditional approach to trial design. For example, in the selection of an optimal sample size no consideration is given to the marginal costs or benefits of sample information. In the traditional approach this can lead to either unbounded or arbitrary sample sizes. This paper presents a decision-analytic approach to trial design which takes explicit account of the costs of sampling, the benefits of sample information and the decision rules of cost-effectiveness analysis. It also provides a consistent framework for setting priorities in research funding and establishes a set of screens (or hurdles) to evaluate the potential cost-effectiveness of research proposals. The framework permits research priority setting based explicitly on the budget constraint faced by clinical practitioners and on the information available prior to prospective research. It demonstrates the link between the value of clinical research and the budgetary restrictions on service provision, and it provides practical tools to establish the optimal allocation of resources between areas of clinical research or between service provision and research.

Mesh:

Year:  1996        PMID: 9003938     DOI: 10.1002/(SICI)1099-1050(199611)5:6<513::AID-HEC237>3.0.CO;2-9

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  76 in total

Review 1.  Systematic review of near patient test evaluations in primary care.

Authors:  B C Delaney; C J Hyde; R J McManus; S Wilson; D A Fitzmaurice; S Jowett; R Tobias; G H Thorpe; F D Hobbs
Journal:  BMJ       Date:  1999-09-25

Review 2.  Modelling in health economic evaluation. What is its place? What is its value?

Authors:  A Brennan; R Akehurst
Journal:  Pharmacoeconomics       Date:  2000-05       Impact factor: 4.981

Review 3.  Handling uncertainty in cost-effectiveness models.

Authors:  A H Briggs
Journal:  Pharmacoeconomics       Date:  2000-05       Impact factor: 4.981

Review 4.  Sample size determination for cost-effectiveness trials.

Authors:  Andrew R Willan
Journal:  Pharmacoeconomics       Date:  2011-11       Impact factor: 4.981

5.  Prioritizing Future Research on Allopurinol and Febuxostat for the Management of Gout: Value of Information Analysis.

Authors:  Eric Jutkowitz; Fernando Alarid-Escudero; Hyon K Choi; Karen M Kuntz; Hawre Jalal
Journal:  Pharmacoeconomics       Date:  2017-10       Impact factor: 4.981

Review 6.  Role of pharmacoeconomic analysis in R&D decision making: when, where, how?

Authors:  Paul Miller
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 7.  Information created to evade reality (ICER): things we should not look to for answers.

Authors:  Stephen Birch; Amiram Gafni
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 8.  The contrast and convergence of Bayesian and frequentist statistical approaches in pharmacoeconomic analysis.

Authors:  Grant H Skrepnek
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

9.  Personalized medicine and genomics: challenges and opportunities in assessing effectiveness, cost-effectiveness, and future research priorities.

Authors:  Rena Conti; David L Veenstra; Katrina Armstrong; Lawrence J Lesko; Scott D Grosse
Journal:  Med Decis Making       Date:  2010-01-04       Impact factor: 2.583

10.  A Need for Change! A Coding Framework for Improving Transparency in Decision Modeling.

Authors:  Fernando Alarid-Escudero; Eline M Krijkamp; Petros Pechlivanoglou; Hawre Jalal; Szu-Yu Zoe Kao; Alan Yang; Eva A Enns
Journal:  Pharmacoeconomics       Date:  2019-11       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.